Yuyang Xiaokui Decoction the Treatment of Ulcerative Colitis Curative Effect Observation

CHEN Hua-wei; ZHONG Jun-hua; YUAN Yong

doi:10.13422/j.cnki.syfjx.2014100192

您当前的位置：

首页 >

文章列表页 >

Yuyang Xiaokui Decoction the Treatment of Ulcerative Colitis Curative Effect Observation

更新时间：2024-01-04

- Yuyang Xiaokui Decoction the Treatment of Ulcerative Colitis Curative Effect Observation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 10, Pages: 192-195(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014100192
  CLC： R259
- Published：2014
- 稿件说明：
移动端阅览
CHEN Hua-wei, ZHONG Jun-hua, YUAN Yong. Yuyang Xiaokui Decoction the Treatment of Ulcerative Colitis Curative Effect Observation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 192-195.
DOI：

CHEN Hua-wei, ZHONG Jun-hua, YUAN Yong. Yuyang Xiaokui Decoction the Treatment of Ulcerative Colitis Curative Effect Observation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 192-195. DOI： 10.13422/j.cnki.syfjx.2014100192.

摘要

目的：观察愈疡消溃方治疗溃疡性结肠炎（UC）活动期近期疗效及对白细胞介数-17，21（IL-17，IL-21）的影响。方法：90例UC患者随机按数字法分为对照组和观察组各45例。对照组采用美沙拉嗪肠溶片，吞服勿咀嚼，1 g/次，4次/d。观察组在对照组基础上加用愈疡消溃I方，1剂/d，常规水煎分2次口服；愈疡消溃Ⅱ方，1剂/d，复煮浓缩至120 mL，睡前灌肠，连续5 d后停灌 2 d。两组疗程均为8周。记录治疗前后Sutherland疾病活动指数（Sutherland DAI），并计算缓解率；观察肠镜表现及结肠组织病理改变情况；记录治疗前后主要症状体、体征评分；检测血清IL-17，IL-21水平。结果：两组治疗后Sutherland DAI评分、肠镜表现评分及肠组织病理改变评分均较治疗前下降（P<0.01），观察组上述指标评分均低于对照组（P<0.01）；两组治疗后腹泻、脓血便、腹痛、腹胀、肛门灼热、里急后重、充血水肿、糜烂评分均较治疗前下降（P<0.01），观察组治疗后上述各主要症状、体征评分均低于对照组（P<0.01）；观察组缓解31例，缓解率68.9%，对照组缓解20例，缓解率44.4%，观察组优于对照组（P<0.01）；治疗后两组血清IL-17，IL-21水平均较治疗前下降（P<0.01），观察组血清IL-17，IL-21水平低于对照组（P<0.01）。结论：愈疡消溃方口服及灌肠能减轻活动期轻、中度UC患者疾病活动程度，能减轻UC患者临床症状、体证，促进其进入缓解期，其作用机制可能与减轻辅助性T细胞17细胞介导的炎证反应有关。

Abstract

Objective: The purpose is to observe recent curative effect of Yuyang Xiaokui decoction in the treatment of ulcerative colitis (UC) active stage and its influence on the leukocyte betweenness-17

21 (IL-17

IL-21). Method: Ninety cases of patients with UC were randomly divided into control group (45 cases) and observation group (45 cases) according to numeric method. The patients in control group took the mesalazin enteric-coated tablets

to swallow not chew

1 g/time

4 times/day. For patients in observation group

they took Yuyang Xiaokui I decoction on the basis of the control group

1 dose/day

conventional water decoction

orally

2 times;Yuyang Xiaokui Ⅱ decoction

1 dose/day

severe times boiling concentration to 120 mL

enema before sleeping

continue 5 days before 2 days suspend. The treatment course was 8 weeks. The Sutherland disease activity index (Sutherland DAI) was recorded before and after treatment and the response rate was calculated. The colonoscopy expression and colon tissue pathological changes were observed. The main symptoms

signs score were recorded before and after the treatment and the level of serum IL-17

IL-21 was detected. Result: After treatment

the Sutherland DAI

colonoscopy performance score and intestinal tissue pathological change score of two groups were decreased (P<0.01)

while the related scores of observation group were all lower than the control group (P<0.01). The diarrhea

purulent blood

abdominal pain

abdominal distension

anus hot

anal congestion edema and erosion rate were decreased (P<0.01)

while the main symptoms and related scores of observation group were all lower than the control group (P<0.01). There are 31 cases remission in observation group and 20 cases remission in control group with remission rate 68.9% and 44.4%

respectively. The observation group is better than that of control group (P<0.01). The levels of serum IL-17

IL-21 of two groups were decreased after treatment (P<0.01)

while the level of serum IL-17

IL-21 of observation group is lower than the control group (P<0.01). Conclusion: The oral taking and enema of Yuyang Xiaokui decoction can reduce degree of disease activity of patients with UC in light and moderate degree of active stage

alleviate clinical symptoms and sign of patients with UC and promote it into remission. Its mechanism may be related to reduce inflammatory reaction that mediated by Th17 cells.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Observation on Jiechang Qingre Pills Combined with Conventional Western Medicine Therapy in Improving Dampness-heat Syndrome of Large Intestine at Active Stage of Ulcerative Colitis

Nano Oral Colon Targeted Drug Delivery System in Treatment of Ulcerative Colitis： A Review

Comparison of Pharmacokinetics and Tissue Distribution of Free Anthraquinones and Gallic Acid in Mice with Ulcerative Colitis Before and After Processing of Rhei Radix et Rhizoma Carbonisata

Mechanisms of Zhuyuwan in Treating both Intrahepatic Cholestasis and Ulcerative Colitis Based on Homotherapy for Heteropathy

Shaoyaotang Containing Serum Mediates Fas/FasL Pathway to Inhibit Lipopolysaccharide Induced Inflammation and Apoptosis of Caco-2 Cells

Related Author

Ya-juan YANG

Kai WANG

Zuo-wu XI

Zong-yue GAO

ZHAO Feiyan

ZHU Wenting

TAN Lin

LUO Wenyu

Related Institution

Second Clinical Medical College， Henan University of Chinese Medicine

Henan Province Hospital of TCM The Second Affiliated Hospital of Henan University of Chinese Medicine

Jiangxi University of Chinese Medicine

College of Food Science and Technology，Nanchang University

School of Life Sciences，Beijing University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰